Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 207-211

  Yang, Tae Hyun ^a   Jin, Han Young ^a   Choi, Kyu Nam ^a   Do, Ungjeong ^a   Kim, Hyung Jun ^a   Chung, Sang Ryul ^a   Seo, Jeong Sook ^a   Jang, Jae Sik ^a   Kim, Dae Kyeong ^a   Kim, Dong Soo ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Cilostazol; Clopidogrel; Point of care systems; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HEMATOMA; HUMAN; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; POINT OF CARE TESTING; PRIORITY JOURNAL; PUNCTURE SITE HEMATOMA; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION ANALYZER;

CILOSTAZOL; CLOPIDOGREL; POINT-OF-CARE SYSTEMS; PRASUGREL;

ADULT; AGED; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; TETRAZOLES; THIOPHENES; TICLOPIDINE;

EID: 84883811170     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.093     Document Type: Article

References (28)

1. M. Gawaz Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium Cardiovasc Res 61 2004 498 511
2. G. Campo, M. Valgimigli, and D. Gemmati Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study J Am Coll Cardiol 48 2006 2178 2185
3. S. King, S. Smith, and J. Hirshfeld 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation 117 2008 261 295
4. L. Jennings Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance Crit Pathw Cardiol 8 2009 20 28
5. P.A. Grubel, and U.S. Tantry Clopidogrel resistance? Thromb Res 120 2007 311 321
6. P.G. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 24 2007 2312 2317
7. T. Cuisset, C. Frere, and J. Quilici Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients Am J Cardiol 104 2009 1078 1082
8. M.J. Price, S. Endemann, and R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
9. R. Marcucci, A. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
10. J.S. Park, and Y.J. Kim The clinical effects of cilostazol on atherosclerotic vascular disease Korean Circ J 38 2008 441 445
11. B.K. Lee, S.W. Lee, and S.W. Park Effects of triple antiplatelet therapy with aspirin, clopidogrel and cilostazol on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation Am J Cardiol 100 2007 610 614
12. Y.H. Jeong, S.W. Lee, and B.R. Choi Randomized comparison of adjunctinve cilostazol versus high maintenance dose clopidogrel in patients with high post-tratment platelet reactivity J Am Coll Cardiol 53 2009 1101 1109
13. T. Jernberg, C.D. Payne, and K.J. Winters Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
14. O.O. Braun, M. Johnell, and C. Varenhorst Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease Thromb Haemost 100 2008 626 633
15. S.D. Wiviott, D. Trenk, and A.L. Frelinger Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention Circulation 116 2007 2923 2932
16. J.A. Jakubowski, C.D. Payne, and Y.G. Li The use of the VerifyNow P2Y12 poit-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and cliopidogrel administration Thromb Haemost 99 2008 409 415
17. T. Jernberg, C.D. Payne, and J.D. Winters Prasugrel achieves greater inhibition of platelet aggregation an a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
18. D. Alexopoulos, I. Xanthopoulou, and P. Davlouros Parsugrel overcomes high on-clopigorel platelet reactivity in chronic coronary artery disease pataients more effectively than high dose (150 mg) clopidogrel Am Heart J 162 2011 733 739
19. A. Sugidachi, T. Ogawa, and A. Kurihara The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite J Thromb Haemost 5 2007 1545 1551
20. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndrome N Engl J Med 357 2007 2001 2015
21. G. Montalescot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial Lancet 373 2009 723 731
22. A. Ryningen, J.B. Olav, and H. Holmsen Elevation of cyclic AMP decreases phosphoinositide turnover and inhibits thrombin-induced secretion in human platelets Biochim Biophys Acta 1394 1998 235 248
23. S.W. Lee, S.W. Park, and M.K. Hong Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis J Am Coll Cardiol 46 2005 1833 1837
24. J.C. Ahn, W.H. Song, and J.A. Kwon Effects of cilostazol on platelet activation in coronary stenting patients already treated with aspirin and clopidogrel Korean J Intern Med 19 2004 230 236
25. K.Y. Chen, S.W. Rha, and Y.J. Li Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Circulation 119 2009 3201 3214
26. M. Gawaz, F.J. Neumann, I. Ott, A. Schiessler, and A. Schomig Platelet function in acute myocardial infarction treated with direct angioplasty Circulation 93 1996 229 237
27. D.W. Park, S.W. Park, and K.H. Park Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up Am J Cardiol 98 2006 352 356
28. N. Breet, J. van Werkum, and H. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762